Cargando…

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4

Detalles Bibliográficos
Autor principal:	Sharma, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072472/ http://dx.doi.org/10.1186/2051-1426-2-S2-I6

Ejemplares similares

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

The ICOS–ICOSL pathway tunes thymic selection
por: Dong, Mengqi, et al.
Publicado: (2022)

Universal access to anti-HIV therapy
por: Souteyrand, Yves
Publicado: (2012)

ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo
por: Stoppa, Ian, et al.
Publicado: (2022)

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response
por: Dalgleish, A, et al.
Publicado: (2014)

Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations
por: Lionetto, Luana, et al.
Publicado: (2015)

Investigator led trials: challenges and opportunities
por: Sandercock, Peter
Publicado: (2011)

PReS13-SPK-1586: Biological agents for the treatment of rheumatic diseases: present and future targets of biologic therapy
por: Mcinnes, I
Publicado: (2013)

Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils
por: Zhou, Aina, et al.
Publicado: (2023)

S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data
por: Shevtsov, M, et al.
Publicado: (2014)

New anti HCV drugs in the pipeline
por: Bourlière, Marc
Publicado: (2010)

Anti-latency agents to purge HIV reservoirs
por: Moreno, Santiago
Publicado: (2012)

Kynurenine pathway metabolites in migraine
por: Nicoletti, Ferdinando
Publicado: (2015)

What does it take to be healthy? Investigating immune-deficiency in non-immunodeficient scenarios
por: Binda, Elisa, et al.
Publicado: (2012)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

Is there a role for cytokine-immune based therapy in HIV disease therapy?
por: Poli, Guido
Publicado: (2010)

A common protein export pathway in malaria parasites
por: Crabb, Brendan, et al.
Publicado: (2010)

New perspectives on immunological pathways underlying peanut-induced anaphylaxis
por: Jordana, Manel
Publicado: (2011)

Statistical issues in the analysis of non-pharmacological therapy trials with clustering by care-provider or therapy group
por: Roberts, Chris
Publicado: (2011)

Transporters used by parasites as drug targets: tempting but underexploited
por: Staines, Henry
Publicado: (2010)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

Hybrids and mini-cutting: a powerful combination that has revolutionized the Eucalyptus clonal forestry
por: Assis, Teotônio Francisco
Publicado: (2011)

Gene therapy to cure HIV? Prospects and realities
por: Hütter, Gero
Publicado: (2012)

Molecular approach to food allergy diagnosis and therapy
por: van Ree, Ronald
Publicado: (2011)

A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum
por: Ward, Steve A, et al.
Publicado: (2010)

PReS13-SPK-1129: Biologic therapies in SLE
por: Isenberg, DA
Publicado: (2013)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Cojocaru, G, et al.
Publicado: (2014)

Novel vaccine and gene therapy approaches against HIV-AIDS
por: Das, A, et al.
Publicado: (2009)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
por: Liu, Z, et al.
Publicado: (2014)

PReS13-SPK-1572: The therapy management of pain amplification syndrome
por: Maillard, S
Publicado: (2013)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

PReS13-SPK-1587: New biologic targets for the future and basic science behind them
por: Prakken, B
Publicado: (2013)

S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing
por: Reuther, S, et al.
Publicado: (2014)

Lighting a candle in the dark: advances in the genetics and (gene) therapy of retinal dystrophies
por: den Hollander, Anneke I
Publicado: (2012)

Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction
por: Nayar, Saba, et al.
Publicado: (2022)

Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome
por: Van den Steen, Philippe E, et al.
Publicado: (2010)

INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
por: Jonchere, Barbara, et al.
Publicado: (2022)

Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases
por: Bellan, Mattia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_so6kc14oqmk0sfae3ru7iutfkg